GLP-1 RAs are established therapeutics shown to provide clinically meaningful reductions in elevated blood sugar, glycated hemoglobin (HbA1C), body weight, blood pressure and cardiovascular risk in patients with type 2 diabetes and obesity20–23. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.